|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
CO-ADMINISTRATION OF CETACHOLAMINE DEPLETOR,SUCH AS RESERPINE, MAY RESULT IN HYPOTENSION AND /OR MARKED TACHYCARDIA WHICH MAY PRODUCE VERTIGO, SYNCOPE OR POSTURAL HYPOTENSION
|
MAY POTENTIATE HYPOTENSIVE EFFECTS
|
PHENYTOIN ANTIEPILEPTIC ACTIVITY IS ANTAGONISED BY THE DRUG BY REDUCING THE CONVULSIVE THRESHOLD, SO PHENYTOIN DOSE HAS TO BE INCREASED
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
MAOI MAY CAUSE CNS EXCITATION ON CONCURRENT USE
|
MAOI MAY CAUSE CNS EXCITATION ON CONCURRENT USE
|
MAOI MAY CAUSE CNS EXCITATION ON CONCURRENT USE
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
INCREASED SEDATIVE EFFECT
|
TETRABENAZINE BLOCKS THE ACTION OF RESERPINE
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
SIGNS OF HYPOGLYCEMIA MAY BE REDUCED OR ABSENT
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
ADDITIVE EFFECT WITH BETABLOCKERS ON AV NODE CONDUCTION
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
LEVODOPA EFFECT IS REDUCED BY THE DRUG
|
CO-ADMINISTRATION CAN CAUSE TACHYCARDIA
|